Arshad Khanani, MD, Sierra Eye Associates/University of Nevada Reno School of Medicine

Arshad Khanani, MD shares his excitement about the potential of elamipretide joining the treatment armamentarium in GA and his final thoughts on the topic.

Arshad Khanani, MD points to the viability of the mechanism of action of elamipretide for geographic atrophy in dry AMD, and what it could represent for patient outcomes.

Arshad Khanani, MD provides insight into the pivotal Phase 3 clinical trials investigating elamipretide for geographic atrophy in dry AMD.

Arshad Khanani, MD discusses the key findings on elamipretide from the Phase 2 ReCLAIM-2 clinical trial.

Arshad Khanani, MD describes the mechanism of action of elamipretide, an investigational product candidate for geographic atrophy in dry age-related macular degeneration.

Dr Arshad Khanani highlights various strategies currently under investigation for the treatment of age-related macular degeneration and explains the impact long-term data and real-world evidence has on his treatment decisions.

Considerations for treating patients with diabetes who have wet age-related macular degeneration with faricimab to reduce treatment burden based on results of recent clinical trials.

An overview of key clinical trials that have explored the potential of faricimab as a treatment option for patients with wet age-related macular degeneration.

The rationale for studying faricimab, a bispecific antibody that targets 2 distinct pathways, as a treatment option for patients with wet age-related macular degeneration.

Based on personal clinical experience, Arshad Khanani, MD, explains his current approach to treating wet age-related macular degeneration with anti-VEGF therapy, with special considerations for appropriate dosage and timing of injections, and describes how he assesses patient response to therapy.

Dr Arshad Khanani describes the role of anti-VEGF therapy for wet age-related macular degeneration and elaborates on factors that impact treatment selection and sequencing in a patient’s continuum of care.

Strategies that can be used to screen and confirm a diagnosis of age-related macular degeneration, as well as monitor patients to optimize care.

Arshad Khanani, MD, defines age-related macular degeneration as it relates to vision loss, highlighting the ways the condition may present in patients and its impact on quality of life.